Sun Pharmaceutical Industries Ltd Launches Global Innovative Drug ILUMYA for Moderate-to-Severe Plaque Psoriasis in India

Sun Pharmaceutical Industries Limited announced the introduction of ILUMYA (tildrakizumab-asmn) in India, marking a significant addition to its specialty biologics portfolio. ILUMYA is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), thereby blocking pro-inflammatory pathways involved in psoriasis.

The drug is administered as a 100 mg subcutaneous injection and is indicated for adult patients with moderate-to-severe plaque psoriasis who have not responded adequately to standard therapies. Clinical trials have demonstrated ILUMYA’s sustained efficacy and a favorable safety profile, with common adverse effects including mild injection-site reactions and upper respiratory infections.

Sun Pharma’s Managing Director Kirti Ganorkar emphasized that ILUMYA provides a vital therapeutic option for patients struggling with this chronic skin condition, reflecting the company's commitment to advancing innovative healthcare solutions in India.

Globally, ILUMYA has shown strong commercial performance and continues to gain approval in multiple markets. In FY25, the drug generated global sales of $681 million, underscoring its growing adoption.

Key Highlights:

Launch of ILUMYA (tildrakizumab) in India for moderate-to-severe plaque psoriasis

Biologic therapy targeting IL-23 p19 subunit to modulate inflammation

Administered as 100 mg subcutaneous injection with a well-established safety profile

Provides new hope for patients inadequately controlled by existing treatments

ILUMYA recorded $681 million in global sales for FY25

Reinforces Sun Pharma’s position in the innovative specialty biologics space

Source: Sun Pharmaceutical Industries Ltd official release, Economic Times, Business Standard